Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

7/16/24 8:07:22 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ONVO alert in real time by email

Get the next $ONVO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ONVO

Date	Price Target	Rating	Analyst

More analyst ratings

$ONVO
Press Releases

Fastest customizable press release news feed in the world

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The meeting was held November 15-19, 2024 in San Diego, California. The presentation entitled "Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agon
11/20/24 8:05:04 AM ET
$ONVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798. "The promise of FXR314 is strong and I encourage investors to review our newest presentation," said Keith Murphy, Executive Chairman. "As mergers and acquisitions continue to be str
7/16/24 8:05:44 AM ET
$ONVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company's lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and preclinical models. DDW2024 is being held in Washington, D.C. May 18-21, 2024. The poster, titled, "Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel d
5/21/24 8:05:35 AM ET
$ONVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

Chat with this insight

Recent Analyst Ratings for
$ONVO

$ONVO
Press Releases

Fastest customizable press release news feed in the world

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

$ONVO
SEC Filings

SEC Form 10-Q filed by Organovo Holdings Inc.

SEC Form S-1 filed by Organovo Holdings Inc.

SEC Form PRE 14A filed by Organovo Holdings Inc.

$ONVO
Market Insights

Live Market Insights

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Organovo Granted U.S. Patent #12037603: Methods for tissue fabrication

Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

$ONVO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Organovo Holdings Inc.

SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

$ONVO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Gobel David was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)

Director Milhous Alison Tjosvold was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)

Director Cohen Douglas Jay was granted 19,607 shares, increasing direct ownership by 40% to 68,821 units (SEC Form 4)

Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

Chat with this insight

Recent Analyst Ratings for $ONVO

$ONVO Press Releases

Fastest customizable press release news feed in the world

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

$ONVO SEC Filings

SEC Form 10-Q filed by Organovo Holdings Inc.

SEC Form S-1 filed by Organovo Holdings Inc.

SEC Form PRE 14A filed by Organovo Holdings Inc.

$ONVO Market Insights

Live Market Insights

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Organovo Granted U.S. Patent #12037603: Methods for tissue fabrication

Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

$ONVO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Organovo Holdings Inc.

SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

$ONVO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Gobel David was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)

Director Milhous Alison Tjosvold was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)

Director Cohen Douglas Jay was granted 19,607 shares, increasing direct ownership by 40% to 68,821 units (SEC Form 4)

Recent Analyst Ratings for
$ONVO

$ONVO
Press Releases

$ONVO
SEC Filings

$ONVO
Market Insights

$ONVO
Large Ownership Changes

$ONVO
Insider Trading